This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Midgette, A. S. Articles by Pauker, S. G. Search for Related Content PubMed PubMed Citation Articles by Midgette, A. S. Articles by Pauker, S. G. Social Bookmarking                         What's this?

Cost - Effectiueness of Streptokinase for Acute Myocardial Infarction

A Combined Meta-analysis and Decision Analysis of the Effects of Infarct Location and of Likelihood of Infarction

John B. Wong

Joni R. Beshansky

Avi Porath

Craig Fleming

Stephen G. Pauker

Objective: To determine the effects of infarct location and of the likelihood of infarction on the cost-effectiveness of intravenous streptokinase (IVSK) for suspected acute myocardial infarction (AMI). Design: A meta-analysis of short-term survival was combined with a simple decision tree to determine marginal cost-effectiveness ratios for different infarct locations and different likelihoods of AMI (pMI). Setting: Six randomized trials comparing IVSK with conservative treatment. Patients: 31,940 patients with onset of symptoms of AMI from four to 24 hours earlier and, with the exception of one trial, electrocardiographic abnormalities. Patients with contraindications to thrombolytic treatment such as uncontrolled hypertension were excluded. Main results: If AMI is certain, treatment with IVSK has marginal cost- effectiveness ratios for each additional life saved of $9,900, $56,600, and $28,400, respec tively, for patients with anterior, inferior, and other locations of AMI. If pMI is 50%, treatment with IVSK has marginal cost-effectiveness ratios for each additional life saved of $22,700, $131,800, and $63,100, respectively, for patients with anterior, inferior, and other locations of AMI. Conclusions: The marginal cost-effectiveness ratio for IVSK therapy of inferior infarction is six times that for anterior infarction and rises steeply as the presence of AMI becomes less certain. Assuming society is willing to pay $250,000 per life saved, IVSK therapy should be given if the chance of acute anterior infarction exceeds 7%, if the chance of inferior infarction exceeds 32%, or if the chance of infarction in other locations exceeds 17%. In patients with suspected acute myocardial infarction, IVSK saves lives and is a reasonable use of societal resources. Key words: thrombolytic therapy; acute myocardial infarction; cost-effectiveness. (Med Decis Making 1994;14:108-117)

Medical Decision Making, Vol. 14, No. 2, 108-117 (1994)
DOI: 10.1177/0272989X9401400203


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				D. Gu, M. Wang, M. Wang, Z. Zhang, and J. Chen The DNA repair gene APE1 T1349G polymorphism and cancer risk: a meta-analysis of 27 case-control studies Mutagenesis, November 1, 2009; 24(6): 507 - 512. [Abstract] [Full Text] [PDF]

				E. J. Stanek, J. W.M. Cheng, P. J. Peeples, R. J. Simko, and S. A. Spinler Patient Preferences for Thrombolytic Therapy in Acute Myocardial Infarction Med Decis Making, October 1, 1997; 17(4): 464 - 471. [Abstract] [PDF]